JP2004526459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004526459A5 JP2004526459A5 JP2002589661A JP2002589661A JP2004526459A5 JP 2004526459 A5 JP2004526459 A5 JP 2004526459A5 JP 2002589661 A JP2002589661 A JP 2002589661A JP 2002589661 A JP2002589661 A JP 2002589661A JP 2004526459 A5 JP2004526459 A5 JP 2004526459A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- antigen
- cells
- specific
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004698 lymphocyte Anatomy 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 108010084313 CD58 Antigens Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 102000005373 Keratin-3 Human genes 0.000 claims 1
- 108010070918 Keratin-3 Proteins 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000012761 co-transfection Methods 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- -1 fibroblast Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001114 myogenic effect Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0106231A FR2824567B1 (fr) | 2001-05-11 | 2001-05-11 | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
| PCT/FR2002/001586 WO2002092793A1 (fr) | 2001-05-11 | 2002-05-10 | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004526459A JP2004526459A (ja) | 2004-09-02 |
| JP2004526459A5 true JP2004526459A5 (enExample) | 2005-12-22 |
| JP4185366B2 JP4185366B2 (ja) | 2008-11-26 |
Family
ID=8863160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589661A Expired - Fee Related JP4185366B2 (ja) | 2001-05-11 | 2002-05-10 | 抗原−特異的Ｔｒ１リンパ球を得る方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8076133B2 (enExample) |
| EP (1) | EP1390474B1 (enExample) |
| JP (1) | JP4185366B2 (enExample) |
| AT (1) | ATE354641T1 (enExample) |
| CA (1) | CA2446981C (enExample) |
| DE (1) | DE60218302T2 (enExample) |
| DK (1) | DK1390474T3 (enExample) |
| ES (1) | ES2282425T3 (enExample) |
| FR (1) | FR2824567B1 (enExample) |
| WO (1) | WO2002092793A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358506B1 (en) | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| EP1061949B1 (en) | 1998-03-03 | 2009-07-15 | University of Southern California | Cytokines and mitogens to inhibit graft-versus-host disease |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| CA2469800A1 (en) * | 2001-12-21 | 2003-07-24 | University Of Southern California | Methods for the induction of professional and cytokine-producing regulatory cells |
| WO2003057171A2 (en) * | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7638326B2 (en) * | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| AU2003292137A1 (en) * | 2002-11-29 | 2004-06-23 | Maria Grazia Roncarolo | Rapamycin and il-10 for the treatment of immune diseases |
| FR2852967B1 (fr) * | 2003-03-26 | 2007-12-07 | Txcell | Procede d'obtention de cellules dendritiques et de cellules t |
| FR2856700B1 (fr) * | 2003-06-24 | 2007-06-08 | Txcell | Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications |
| WO2005046729A2 (en) * | 2003-11-12 | 2005-05-26 | Txcell | Use of lipopeptides for activating t lymphocytes through the skin |
| ES2653570T3 (es) | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| US7985409B2 (en) | 2004-08-11 | 2011-07-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Tr1 cells for use in atherosclerosis |
| EP1812563B1 (en) * | 2004-10-29 | 2013-04-10 | Benaroya Research Institute at Virginia Mason | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use |
| EP1712615A1 (en) * | 2005-04-15 | 2006-10-18 | Txcell | In vitro production of a cell population using feeder cells |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| ATE513903T1 (de) * | 2005-07-01 | 2011-07-15 | Txcell S A | Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc |
| EA015989B1 (ru) * | 2005-08-31 | 2012-01-30 | АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ | Лечение воспалительного заболевания кишечника |
| GB0603081D0 (en) * | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| JP5543207B2 (ja) * | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| EP2185936A4 (en) * | 2007-08-02 | 2010-08-04 | Iss Immune System Stimulation | DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE |
| JP5539886B2 (ja) * | 2007-10-17 | 2014-07-02 | ティクセル | Ｔｒ１細胞、間葉系幹細胞およびその使用 |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| EP2062970A1 (en) * | 2007-11-26 | 2009-05-27 | Txcell | Compositions for treating an intestinal inflammatory condition |
| SI2113254T1 (sl) | 2008-04-28 | 2013-01-31 | Txcell | Sestave za zdravljenje vnetnih avtoimunskih stanj |
| EP2113560A1 (en) * | 2008-04-28 | 2009-11-04 | TXCell | Compositions for treating an arthritic condition |
| CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2221364A1 (en) | 2009-02-23 | 2010-08-25 | TXCell | Compositions for treating an allergic or asthmatic condition |
| EP2412802A1 (en) * | 2010-07-29 | 2012-02-01 | TXCell | IL-13 producing TR1-like cells and use thereof |
| EP2439534A1 (en) | 2010-10-08 | 2012-04-11 | TXCell | Method for assessing the efficacy of a TR1 cell therapy in asubject |
| BR112013023968A2 (pt) | 2011-03-25 | 2016-12-13 | Txcell | uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune |
| EP2982746A1 (en) | 2014-08-07 | 2016-02-10 | TXCell | Regulatory T cells with therapeutic potential |
| AU2019269601A1 (en) | 2018-05-17 | 2020-11-26 | Regents Of The University Of Minnesota | Drug-resistant immune cells and methods of use thereof |
| WO2019237378A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 一种将CD274基因定点整合至Jurkat细胞的方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277635B1 (en) * | 1992-03-04 | 2001-08-21 | Schering Corporation | Use of interleukin-10 to produce a population of suppressor cells |
| DE69734974D1 (de) * | 1996-02-08 | 2006-02-02 | Us Gov Health & Human Serv | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen |
| CA2254975C (en) * | 1996-05-23 | 2008-12-16 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells |
| US6746670B2 (en) * | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
| US6670146B2 (en) * | 2000-10-04 | 2003-12-30 | Schering Corporation | Regulatory T cells; methods |
-
2001
- 2001-05-11 FR FR0106231A patent/FR2824567B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-10 JP JP2002589661A patent/JP4185366B2/ja not_active Expired - Fee Related
- 2002-05-10 US US10/477,671 patent/US8076133B2/en not_active Expired - Fee Related
- 2002-05-10 DE DE60218302T patent/DE60218302T2/de not_active Expired - Lifetime
- 2002-05-10 WO PCT/FR2002/001586 patent/WO2002092793A1/fr not_active Ceased
- 2002-05-10 CA CA2446981A patent/CA2446981C/fr not_active Expired - Fee Related
- 2002-05-10 ES ES02740789T patent/ES2282425T3/es not_active Expired - Lifetime
- 2002-05-10 DK DK02740789T patent/DK1390474T3/da active
- 2002-05-10 AT AT02740789T patent/ATE354641T1/de not_active IP Right Cessation
- 2002-05-10 EP EP02740789A patent/EP1390474B1/fr not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/928,189 patent/US20080233095A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004526459A5 (enExample) | ||
| Tang et al. | Regulatory T-cell therapy in transplantation: moving to the clinic | |
| EP1390474B1 (fr) | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene | |
| US20230310562A1 (en) | Antigen presenting scaffolds for immune-cell manipulation | |
| Arens et al. | Plasticity in programming of effector and memory CD8+ T‐cell formation | |
| Moser et al. | γδ T-APCs: a novel tool for immunotherapy? | |
| JP2006020648A5 (enExample) | ||
| Ureta et al. | Generation of dendritic cells with regulatory properties | |
| Northrop et al. | CD8+ T-cell memory: only the good ones last | |
| US8603815B2 (en) | CD4+ CD25− T cells and Tr1-like regulatory T cells | |
| JP2002539805A5 (enExample) | ||
| Xia et al. | Prevention of allograft rejection by amplification of Foxp3+ CD4+ CD25+ regulatory T cells | |
| Milward et al. | Enhancing human regulatory T cells in vitro for cell therapy applications | |
| IL273698B2 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| Freudenthal et al. | Human blood dendritic cells | |
| JP2002500872A5 (enExample) | ||
| Moberg | An appreciation of Ralph Marvin Steinman (1943–2011) | |
| Chen et al. | Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival | |
| Arthur et al. | Dental pulp stem cells | |
| Au et al. | A strategy to purify, expand and gene-mark regulatory T cells (tregs) for use in the treatment of chronic Graft-Versus-Host Disease (GVHD) | |
| EP1391504A1 (en) | CD4+ CD25- T cells and Tr1-like regulatory T cells | |
| Heeger | What's new and what's hot in transplantation: basic science ATC 2003 | |
| Yingxi et al. | Strategies for Generating Regulatory Dendritic Cells and the Clinical Application of Immune Tolerance. | |
| LESHEM et al. | Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture | |
| Moreau et al. | Semi-mature Bone Marrow Derived DC Expand Foxp3+ CD4+ CD25+ CD127-Regulatory T Cells with Suppressive Activity in the Macaque |